Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
24.76%
Operating Margin
14.70%
Net Margin
12.04%
Efficiency Metrics
Revenue per Expense Ratio
1.17
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
15.85%
Income Tax Rate
22.19%
EPS
20.1700000000
Balance Sheet Analysis
Current Ratio
22.16
Cash Ratio
3.39
Working Capital
$5.75B
Debt to Equity
0.23
Debt to Assets
16.72%
Equity Ratio
72.59%
Cash Flow Analysis
Operating Cash Flow Ratio
5.79%
Free Cash Flow Ratio
5.17%
CapEx to Revenue
0.62%
Dividends Paid
$39.53M
Stock Buybacks
$59.07M
Total Shareholder Returns
$98.60M
Cash Position Change
6.93%
Key Takeaways (2023 FY)
Revenue declined by 2.5386962592531%, indicating potential market challenges
Detailed Growth Metrics
Core Performance
Revenue
-2.54%
Net Income
-25.54%
EPS
-25.41%
Operating Income
-30.01%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
19.44%
Operating Cash Flow
-12.26%
Free Cash Flow
-16.10%
Balance Sheet Health
Assets
10.07%
Debt
-7.68%
Book Value per Share
17.01%
Inventory
8.33%
Shareholder Returns
Dividends per Share
0.00%
Shares Outstanding
-0.20%
Long Term Trends
3Y Revenue/Share
40.30%
5Y Revenue/Share
89.70%
3Y Dividend/Share
0.00%
5Y Dividend/Share
0.00%